Translating patient uniqueness into unique patient treatments
with an innovative personalised immunotherapy platform
based on artificial intelligence and synthetic DNA technology

One of the major hurdles in the fight against cancer is that each tumour is genetically unique
and has specific tumour markers.

Odimma has designed a next-generation precision immunotherapy platform
able to induce a powerful cellular immune response against specific tumours markers
as well as a strong anti-tumoural effect in several aggressive models such as melanoma, colorectal and breast cancer.